We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





ECCMID 2022 Takes Place for the First Time as Hybrid Event Both Onsite and Online

By LabMedica International staff writers
Posted on 22 Apr 2022

The 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022) took place in Lisbon, Portugal from April 23-26 – for the first time as a hybrid event both onsite and online. More...

ECCMID is the world’s premier clinical microbiology & infectious diseases event organized by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID, Basel, Switzerland) that brings together experts from many fields to present their latest findings, guidelines and experiences to an audience of over 14,000 colleagues. This year, the congress featured a hybrid format to facilitate an onsite and online experience for attendees allowing for remote and face-to-face opportunities to take part in the multifaceted program.

ECCMID 2022 offered excellent opportunities to corporate partners to showcase their latest findings, share their experiences and knowledge and demonstrate practical techniques and guidance. A comprehensive program covered the entire range of ECCMID topics with high-level speakers. Participants had the opportunity to meet researchers from many parts of the world to discuss methods, results and the impact on clinical and laboratory practice. Additionally, young professionals had the opportunity to discuss their ideas and projects with renowned experts in a variety of interactive sessions that also provided networking opportunities.

This year’s ECCMID once again featured pipeline corners where innovative companies and research groups were offered a platform to present their early-stage antimicrobial therapies, diagnostic products in development, and research funding opportunities to a wider audience. This was complemented by scientific content co-developed with the industry such as the integrated symposia.

Other new features from ECCMID 2021 that returned this year were the Keynote Fireplace sessions where ECCMID keynote speakers met with a small group of participants to enter a more in-depth discussion on their keynote lecture. Additionally, the infectious disease-themed Escape Room was reprised and updated as an immersive interactive addition.

Related Links:
ESCMID 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Blood Culture Control Panel
Gram-Negative Blood Culture Control Panel
New
Chlamydia Pneumoniae Test
Chlamydia Pneumoniae (CP) Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.